Top Markets
Coin of the day
Harpoon Therapeutics, Inc. Harpoon Therapeutics, Inc.

Harpoon Therapeutics, Inc.

HARP
株式のランク #23352
Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to... Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to immunotherapy, focused on engineering a novel class of T cell activators. These therapies are designed to leverage the body's own immune system to fight cancer and other diseases in patients across the United States. The company's innovative Tri-specific T cell activating construct (TriTAC) platform forms the basis of its development pipeline. This includes HPN328, currently undergoing Phase I/II clinical trials for small cell lung cancer and tumors that express Delta-like canonical Notch ligand 3; HPN217, also in Phase I/II trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical evaluation for ovarian and pancreatic cancers, alongside other mesothelin-expressing tumors. Furthermore, Harpoon has a preclinical asset, HPN601, aimed at various solid tumor indications. The company has also established a discovery collaboration and licensing agreement with AbbVie Biotechnology Ltd. to develop and market products combining its unique TriTAC technology with soluble T cell receptors. Founded in 2015, Harpoon Therapeutics, Inc. is headquartered in South San Francisco, California.
株価
$23.01
最終同期: 2024-03-11
時価総額
$74.80M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Harpoon Therapeutics, Inc. (HARP)

カテゴリー

Harpoon Therapeutics, Inc.(HARP)の発行済株式数
August 2026 時点の発行済株式数 0
Harpoon Therapeutics, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 0 です。August 2026 の終わりには、同社は 0 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Harpoon Therapeutics, Inc.(HARP)の発行済株式数の履歴(2026 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
提供された日付のデータは十分ではありません。
類似企業や競合他社の発行済株式数
企業 発行済株式数
253.90M -
US
62.19M -
NL
396.00M -
US
478.91M -
AU
- -
CH